Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)
Open Access
- 25 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Egyptian Liver Journal
- Vol. 11 (1), 1-8
- https://doi.org/10.1186/s43066-021-00121-8
Abstract
Background Hepatitis B virus (HBV) may reactivate when treating chronic hepatitis C (CHC) with direct-acting antivirals (DAA). We aimed to investigate the risk of HBV infection and reactivation during DAA therapy by performing a prospective observational study carried on 200 patients positive for chronic HCV who were candidates for treatment by DAA therapy according to the Egyptian guidelines from February 2019 to December 2019; the patients identified to carry HBsAg at baseline or with positive HBc Abs were further assessed for other HBV markers: hepatitis B e antigen at baseline, and serum HBV DNA quantitative measurement at baseline, week 4 of treatment, end of treatment. On the other hand, recent infection by HBV among those patients was observed. Results Of all participants, 49% were males and 51% were females, aged above 18 years. There is a highly statistically significant difference (p-value < 0.05) between HCV RNA PCR (at the beginning, at the end of 4 weeks, and at the end of 12 weeks) in studied patients. There was a highly statistically significant difference found between the liver function tests at the beginning, at the end of 4 weeks, and at the end of 12 weeks of treatment where it shows improvement except for serum albumin. At beginning of the study, there were 34 patients who are co-infected with HCV and HBV with quantitative PCR test for HBV DNA ≥ 20 IU/ml. After 1 month of DAA therapy, reactivation was detected in 6 cases (4 occult cases show reverse seroconversion (became HBs Ag positive), and 2 co-infected cases show increased HBV DNA > 1000 IU/L above the baseline level). In addition, 3 new cases acquired recent infection with the positivity of HBc IgM and detectable levels of HBV DNA. After 3 months of study, reactivation was detected in one patient with co-infection (where increased HBV DNA > 1000 IU/L above the baseline level), and 5 new cases acquired recent infection late in the study. Conclusion Screening for HBV infection prior to DAA therapy is required to detect recent infection of reactivation of previous infection during or after DAA therapy.Keywords
This publication has 19 references indexed in Scilit:
- Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus InfectionOpen Forum Infectious Diseases, 2017
- EASL Recommendations on Treatment of Hepatitis C 2016Journal of Hepatology, 2016
- Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral AgentsClinical Gastroenterology and Hepatology, 2016
- The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatmentLiver International, 2016
- Hepatitis C virus infection in Taiwan: Past, present, and futureJournal of the Formosan Medical Association, 2016
- AASLD guidelines for treatment of chronic hepatitis BJournal of Hepatology, 2015
- Evaluation of Aspartate Aminotransferase-to- Platelet Ratio Index as a Non-Invasive Marker for Liver CirrhosisJournal of Clinical and Diagnostic Research, 2015
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusJournal of Hepatology, 2015
- Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysisJournal of Hepatology, 2010
- Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age?The Journal of Infectious Diseases, 2001